Many patients prefer to return to the clinic for next-day pegfilgrastim administration

A patient survey evaluated preference for pegfilgrastim product administration and value of next-day visits1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) suggest pegfilgrastim use to support clinical outcomes during chemotherapy.†2

See the guidelines

UDENYCA® delivers the reliable outcomes you expect, but with 35% cost savings per dose vs Neulasta®.*3

Discover the value of UDENYCA®

UDENYCA® was confirmed to be highly similar to Neulasta®, with no clinically meaningful differences.1,4,5

View proven biosimilarity

* Based on wholesale acquisition cost (WAC). WAC does not necessarily reflect actual prices paid by consumers, pharmacies, or third-party payers. UDENYCA® WAC of $4175 per prefilled syringe vs Neulasta® WAC of $6417 per prefilled syringe.

Other suggestions for therapy are included in the NCCN Guidelines®.

References: 1. Data on file. Coherus BioSciences, Inc.; 2021. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed September 30, 2022. To view the most recent and complete version of the guidelines, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Data on file. Coherus BioSciences, Inc.; 2022. 4. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2021. 5. Neulasta® (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2021.